# A Phase III Long Term Study of K-877 Extended Release Tablet

Study · id `cardio:ct-nct04716595` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04716595](<https://clinicaltrials.gov/study/NCT04716595>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04716595

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT04716595. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2022-06-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT04716595, source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)
- Started: 2021-02-01 (actual) (ClinicalTrials.gov record NCT04716595, source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)
- Primary completion: 2022-06-13 (actual) (ClinicalTrials.gov record NCT04716595, source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)
- Completion: 2022-06-13 (actual) (ClinicalTrials.gov record NCT04716595, source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT04716595, source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04716595-2025-11-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Long Term Study of K-877 Extended Release Tablet
- Condition: Dyslipidemias
- Intervention (Drug): K-877 ER 0.2 mg/day morning administration (once daily)
- Intervention (Drug): K-877 ER 0.2 mg/day evening administration (once daily)
- Lead sponsor: Kowa Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study (`cardio:pubmed-39924184`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e6a26ba72ef14c294bd5383fd1bd8facaa919f789c8d3bd9b2357d78733551da
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
